| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rad51 Recombinase | 13 | 2021 | 81 | 3.600 |
Why?
|
| Homologous Recombination | 9 | 2022 | 57 | 2.200 |
Why?
|
| Radiation Injuries | 3 | 2019 | 158 | 1.230 |
Why?
|
| DNA Repair | 12 | 2021 | 361 | 1.110 |
Why?
|
| Radiotherapy | 5 | 2019 | 320 | 1.040 |
Why?
|
| Endometrial Neoplasms | 11 | 2001 | 227 | 0.950 |
Why?
|
| Small Molecule Libraries | 3 | 2016 | 69 | 0.870 |
Why?
|
| Neoplasms | 7 | 2016 | 3169 | 0.790 |
Why?
|
| Morpholines | 3 | 2015 | 61 | 0.770 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 641 | 0.770 |
Why?
|
| Transcription Factor RelB | 1 | 2022 | 3 | 0.750 |
Why?
|
| Benzamides | 3 | 2015 | 246 | 0.680 |
Why?
|
| Sulfonamides | 3 | 2015 | 331 | 0.620 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2019 | 96 | 0.610 |
Why?
|
| NF-kappa B | 1 | 2022 | 408 | 0.610 |
Why?
|
| Pyrroles | 4 | 2019 | 165 | 0.590 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 2303 | 0.590 |
Why?
|
| Quinoxalines | 1 | 2019 | 51 | 0.580 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 147 | 0.560 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1133 | 0.530 |
Why?
|
| DNA Helicases | 2 | 2015 | 89 | 0.510 |
Why?
|
| Anthracyclines | 1 | 2017 | 31 | 0.510 |
Why?
|
| Sarcoma | 3 | 2019 | 222 | 0.480 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 381 | 0.480 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 196 | 0.470 |
Why?
|
| DNA Replication | 4 | 2019 | 168 | 0.460 |
Why?
|
| Lung Neoplasms | 8 | 2023 | 2365 | 0.450 |
Why?
|
| Enzyme Activation | 2 | 2013 | 674 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 1073 | 0.440 |
Why?
|
| Radiotherapy, Conformal | 2 | 2007 | 88 | 0.420 |
Why?
|
| Adenocarcinoma | 6 | 2012 | 1173 | 0.410 |
Why?
|
| Drug Therapy | 1 | 2014 | 68 | 0.410 |
Why?
|
| Humans | 59 | 2023 | 93515 | 0.410 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2013 | 41 | 0.400 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 64 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 1338 | 0.390 |
Why?
|
| Rec A Recombinases | 1 | 2013 | 14 | 0.390 |
Why?
|
| Maleimides | 1 | 2012 | 27 | 0.390 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 740 | 0.380 |
Why?
|
| DNA Damage | 3 | 2017 | 389 | 0.370 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2009 | 314 | 0.370 |
Why?
|
| Escherichia coli Proteins | 1 | 2013 | 179 | 0.360 |
Why?
|
| Indoles | 1 | 2013 | 303 | 0.360 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2022 | 72 | 0.350 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1234 | 0.350 |
Why?
|
| Cisplatin | 4 | 2009 | 568 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 2544 | 0.320 |
Why?
|
| HEK293 Cells | 4 | 2019 | 696 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1448 | 0.310 |
Why?
|
| Neoplasm Staging | 15 | 2023 | 2017 | 0.300 |
Why?
|
| Protein Binding | 5 | 2019 | 1534 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2009 | 512 | 0.300 |
Why?
|
| Cell Survival | 4 | 2019 | 1004 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 3110 | 0.290 |
Why?
|
| Molecular Structure | 3 | 2019 | 307 | 0.280 |
Why?
|
| Prognosis | 13 | 2021 | 3911 | 0.280 |
Why?
|
| DNA | 6 | 2021 | 1265 | 0.280 |
Why?
|
| Apoptosis | 3 | 2019 | 1721 | 0.280 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2007 | 44 | 0.270 |
Why?
|
| Cranial Irradiation | 1 | 2007 | 40 | 0.270 |
Why?
|
| Female | 35 | 2021 | 48702 | 0.260 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 3830 | 0.260 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 422 | 0.260 |
Why?
|
| Aged | 25 | 2021 | 20434 | 0.250 |
Why?
|
| Nasolacrimal Duct | 1 | 2006 | 2 | 0.240 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2006 | 2 | 0.240 |
Why?
|
| Genomic Instability | 3 | 2017 | 88 | 0.240 |
Why?
|
| Intubation | 1 | 2006 | 21 | 0.240 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 2755 | 0.240 |
Why?
|
| Retrospective Studies | 19 | 2023 | 10164 | 0.230 |
Why?
|
| Middle Aged | 27 | 2021 | 27573 | 0.230 |
Why?
|
| Ovariectomy | 3 | 2001 | 91 | 0.220 |
Why?
|
| Adult | 23 | 2021 | 27918 | 0.210 |
Why?
|
| Hysterectomy | 3 | 2001 | 167 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 636 | 0.200 |
Why?
|
| Multiprotein Complexes | 2 | 2021 | 106 | 0.200 |
Why?
|
| Genes, p53 | 1 | 2003 | 108 | 0.190 |
Why?
|
| Attitude to Health | 1 | 2004 | 217 | 0.190 |
Why?
|
| Survival Analysis | 9 | 2017 | 1524 | 0.190 |
Why?
|
| Fractures, Spontaneous | 1 | 2023 | 16 | 0.190 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 1723 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2004 | 109 | 0.190 |
Why?
|
| HIV-1 | 2 | 2015 | 173 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2017 | 9099 | 0.180 |
Why?
|
| Adenoviridae | 1 | 2003 | 340 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 813 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 155 | 0.180 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1660 | 0.170 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 7061 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 49 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2001 | 42 | 0.170 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 129 | 0.170 |
Why?
|
| Brachytherapy | 6 | 2001 | 126 | 0.170 |
Why?
|
| Orthopedics | 1 | 2023 | 134 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2023 | 150 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 106 | 0.170 |
Why?
|
| Genetic Therapy | 1 | 2003 | 366 | 0.160 |
Why?
|
| Peptides | 1 | 2004 | 656 | 0.160 |
Why?
|
| Extremities | 2 | 2013 | 176 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 5 | 2001 | 572 | 0.150 |
Why?
|
| Ossification, Heterotopic | 1 | 2019 | 32 | 0.150 |
Why?
|
| Adnexa Uteri | 1 | 1999 | 11 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 378 | 0.150 |
Why?
|
| Cycloaddition Reaction | 1 | 2019 | 6 | 0.150 |
Why?
|
| Radiotherapy Dosage | 4 | 2009 | 472 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 409 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2001 | 1775 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 190 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 124 | 0.140 |
Why?
|
| Naphthyridines | 1 | 2019 | 27 | 0.140 |
Why?
|
| Survival Rate | 7 | 2021 | 1948 | 0.140 |
Why?
|
| Radiobiology | 1 | 2018 | 13 | 0.140 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 410 | 0.130 |
Why?
|
| Male | 17 | 2021 | 44557 | 0.130 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 504 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 337 | 0.130 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 120 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2007 | 193 | 0.130 |
Why?
|
| Pneumonectomy | 2 | 2011 | 217 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 96 | 0.130 |
Why?
|
| Endosonography | 1 | 2017 | 100 | 0.130 |
Why?
|
| Risk | 3 | 2004 | 657 | 0.120 |
Why?
|
| Bronchi | 1 | 2017 | 225 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 761 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2011 | 1170 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2019 | 396 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2009 | 284 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2011 | 1061 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 62 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 1077 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 399 | 0.100 |
Why?
|
| Fluorometry | 1 | 2013 | 30 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 379 | 0.100 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2013 | 100 | 0.090 |
Why?
|
| Chicago | 3 | 2001 | 1464 | 0.090 |
Why?
|
| Mitomycin | 1 | 2012 | 29 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2014 | 824 | 0.090 |
Why?
|
| Actuarial Analysis | 3 | 2001 | 60 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2000 | 318 | 0.090 |
Why?
|
| DNA, Single-Stranded | 2 | 2011 | 95 | 0.090 |
Why?
|
| Cross-Linking Reagents | 1 | 2012 | 89 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 246 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2012 | 120 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 37 | 0.090 |
Why?
|
| Virus Integration | 1 | 2011 | 17 | 0.090 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2001 | 9 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 111 | 0.090 |
Why?
|
| Life Tables | 2 | 2001 | 46 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2022 | 3502 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2011 | 71 | 0.090 |
Why?
|
| Esophageal Neoplasms | 2 | 2007 | 344 | 0.090 |
Why?
|
| Cysteine | 1 | 2012 | 145 | 0.090 |
Why?
|
| Age Factors | 3 | 2007 | 1906 | 0.090 |
Why?
|
| Mice | 3 | 2019 | 12269 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 446 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2013 | 124 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2011 | 162 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2000 | 985 | 0.080 |
Why?
|
| Animals | 4 | 2019 | 28155 | 0.080 |
Why?
|
| Child | 2 | 2016 | 7355 | 0.080 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2001 | 61 | 0.080 |
Why?
|
| Chromatin | 1 | 2014 | 440 | 0.080 |
Why?
|
| Binding Sites | 1 | 2012 | 1133 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2011 | 524 | 0.080 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 263 | 0.080 |
Why?
|
| Epirubicin | 1 | 2009 | 14 | 0.080 |
Why?
|
| Ifosfamide | 1 | 2009 | 37 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2012 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 204 | 0.070 |
Why?
|
| History, 19th Century | 1 | 2009 | 56 | 0.070 |
Why?
|
| Enzyme Stability | 1 | 2008 | 41 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2562 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2011 | 317 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2009 | 187 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2009 | 321 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 829 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2009 | 314 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2007 | 29 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2006 | 292 | 0.070 |
Why?
|
| Quality of Life | 1 | 2016 | 1780 | 0.070 |
Why?
|
| Ligands | 1 | 2008 | 476 | 0.060 |
Why?
|
| Genes, BRCA2 | 1 | 2008 | 162 | 0.060 |
Why?
|
| Glutamates | 1 | 2007 | 84 | 0.060 |
Why?
|
| Dacryocystorhinostomy | 1 | 2006 | 3 | 0.060 |
Why?
|
| Silicones | 1 | 2006 | 21 | 0.060 |
Why?
|
| Guanine | 1 | 2007 | 194 | 0.060 |
Why?
|
| Carboplatin | 1 | 2007 | 322 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2008 | 756 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2017 | 3054 | 0.060 |
Why?
|
| London | 1 | 2004 | 15 | 0.050 |
Why?
|
| Bacteriophage M13 | 1 | 2004 | 8 | 0.050 |
Why?
|
| Safe Sex | 1 | 2004 | 24 | 0.050 |
Why?
|
| Adolescent | 3 | 2007 | 9606 | 0.050 |
Why?
|
| Condoms | 1 | 2004 | 38 | 0.050 |
Why?
|
| Pregnancy in Adolescence | 1 | 2004 | 27 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2004 | 174 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 123 | 0.050 |
Why?
|
| Peptide Library | 1 | 2004 | 84 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2004 | 99 | 0.050 |
Why?
|
| Awareness | 1 | 2004 | 89 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 175 | 0.050 |
Why?
|
| Focus Groups | 1 | 2004 | 184 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1799 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2006 | 917 | 0.050 |
Why?
|
| Stents | 1 | 2006 | 409 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2479 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 555 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 148 | 0.050 |
Why?
|
| HIV Infections | 1 | 2011 | 961 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 422 | 0.040 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2001 | 12 | 0.040 |
Why?
|
| Platinum | 1 | 2021 | 67 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 84 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2021 | 404 | 0.040 |
Why?
|
| China | 1 | 2021 | 264 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1741 | 0.040 |
Why?
|
| Infant | 1 | 2007 | 3220 | 0.040 |
Why?
|
| Young Adult | 2 | 2013 | 6930 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1914 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 114 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2001 | 152 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2007 | 3829 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2000 | 21 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2021 | 342 | 0.040 |
Why?
|
| Carcinoma | 2 | 2000 | 439 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2441 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 1999 | 624 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 100 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 2910 | 0.040 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 24 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2464 | 0.040 |
Why?
|
| Oxygen | 1 | 2004 | 769 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 304 | 0.040 |
Why?
|
| Vagina | 1 | 2000 | 177 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2021 | 914 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 884 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 116 | 0.040 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 111 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1999 | 145 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 3147 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2011 | 229 | 0.030 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2015 | 18 | 0.030 |
Why?
|
| Stilbenes | 1 | 2015 | 26 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 26 | 0.030 |
Why?
|
| Mutagens | 1 | 2015 | 29 | 0.030 |
Why?
|
| Replication Protein A | 1 | 2015 | 16 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2015 | 45 | 0.030 |
Why?
|
| Remission Induction | 2 | 2011 | 738 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 266 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 797 | 0.030 |
Why?
|
| Virus Replication | 1 | 2015 | 284 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 555 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2011 | 5 | 0.020 |
Why?
|
| SEER Program | 1 | 2013 | 235 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 17 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 402 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1301 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 259 | 0.020 |
Why?
|
| Time Factors | 1 | 1999 | 5410 | 0.020 |
Why?
|
| Risk Factors | 1 | 2001 | 5899 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 419 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 326 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 75 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1531 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 335 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1261 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 4560 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1768 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 162 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 122 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 149 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 4272 | 0.010 |
Why?
|
| Hospitalization | 1 | 2000 | 937 | 0.010 |
Why?
|